🏅 FDA Orphan Designation

Eohilia

budesonide

Manufacturer: Takeda Pharmaceuticals U.S.A., Inc.

Indicated for:

NON RARE IN EUROPE: Eosinophilic esophagitisOrphan

FDA-Approved Indications (1)

NON RARE IN EUROPE: Eosinophilic esophagitisOrphan Designation

treatment for 12 weeks in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE)

Indications & Usage

1 INDICATIONS AND USAGE EOHILIA ™ is indicated for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE). Limitations of Use EOHILIA has not been shown to be safe and effective for the treatment of EoE for longer than 12 weeks [see Dosage and Administration (2.1) , Clinical Studies (14) ]. EOHILIA is a corticosteroid indicated for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE). ( 1 ) Limitations of Use EOHILIA has not been shown to be safe and effective for the treatment of EoE for longer than 12 weeks. ( 1 , 2.1 , 14 )

💙 Support Programs

View all →

Eohilia

Takeda

Copay card ↗Apply ↗

Eohilia

Takeda Pharmaceuticals U.S.A., Inc.

Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.